A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease.
Gleason grade
polygenic risk score
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
received:
29
10
2021
revised:
17
11
2021
accepted:
18
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Despite the high prevalence of prostate cancer in older men, the predictive value of a polygenic risk score (PRS) remains uncertain in men aged ≥70 years. We used a 6.6 million-variant PRS to predict the risk of incident prostate cancer in a prospective study of 5701 men of European descent aged ≥70 years (mean age 75 years) enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) clinical trial. The study endpoint was prostate cancer, including metastatic or non-metastatic disease, confirmed by an expert panel. After excluding participants with a history of prostate cancer at enrolment, we used a multivariable Cox proportional hazards model to assess the association between the PRS and incident prostate cancer risk, adjusting for covariates. Additionally, we examined the distribution of Gleason grade groups by PRS group to determine if a higher PRS was associated with higher grade disease. We tested for interaction between the PRS and aspirin treatment. Logistic regression was used to independently assess the association of the PRS with prevalent (pre-trial) prostate cancer, reported in medical histories. During a median follow-up time of 4.6 years, 218 of the 5701 participants (3.8%) were diagnosed with prostate cancer. The PRS predicted incident risk with a hazard ratio (HR) of 1.52 per standard deviation (SD) (95% confidence interval (CI) 1.33-1.74,
Identifiants
pubmed: 34830967
pii: cancers13225815
doi: 10.3390/cancers13225815
pmc: PMC8616400
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the National Health and Medical Research Council of Australia, and by Monash University and the Victorian Cancer Agency
ID : 334047 and 1127060
Organisme : NCI Outstanding Investigator Award
ID : R35 CA253185 and K07CA218377
Organisme : National Heart Foundation Future Leader Fellowship
ID : ID 102604
Organisme : NHMRC Leadership Fellowship Investigator Grant
ID : ID 1173690
Organisme : the National Institute on Aging and the National Cancer Institute at the Na-tional Institutes of Health
ID : U01AG029824 and U19AG062682
Organisme : ASPREE Flagship cluster grant (including the Common-wealth Scientific and Industrial Research Organisation, Monash University, Menzies Research In-stitute, Australian National University, University of Melbourne)
ID : NA
Organisme : NIA NIH HHS
ID : P30 AG024824
Pays : United States
Références
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Sci Rep. 2020 Oct 13;10(1):17075
pubmed: 33051487
Int J Cancer. 2020 Oct 15;147(8):2142-2149
pubmed: 32338768
JAMA. 2014 Mar 19;311(11):1143-9
pubmed: 24643604
Med J Aust. 2019 Mar;210(4):168-173
pubmed: 30835844
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Contemp Clin Trials. 2013 Nov;36(2):555-64
pubmed: 24113028
N Engl J Med. 2018 Oct 18;379(16):1499-1508
pubmed: 30221596
Nat Genet. 2021 Apr;53(4):420-425
pubmed: 33692568
N Engl J Med. 2018 Oct 18;379(16):1509-1518
pubmed: 30221597
Prostate. 2020 Nov;80(15):1314-1321
pubmed: 33258481
Lancet Oncol. 2014 Oct;15(11):e484-92
pubmed: 25281467
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
Genet Med. 2015 Oct;17(10):789-95
pubmed: 25569441
Nat Med. 2020 Apr;26(4):549-557
pubmed: 32273609
Ann Oncol. 2015 May;26(5):848-864
pubmed: 25403590
Cancers (Basel). 2021 Jul 14;13(14):
pubmed: 34298747
N Engl J Med. 2018 Oct 18;379(16):1519-1528
pubmed: 30221595
Eur Urol Focus. 2019 Sep;5(5):756-787
pubmed: 29576530
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
World J Urol. 2017 Jun;35(6):867-874
pubmed: 27518576
Nat Clin Pract Urol. 2009 Feb;6(2):87-95
pubmed: 19198622
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33947030
Cancer Discov. 2020 Dec;10(12):1808-1825
pubmed: 33139244
Prostate. 2015 Mar 1;75(4):390-8
pubmed: 25408531
Aging Cell. 2021 Jun;20(6):e13384
pubmed: 34041846
Cancer Res. 2021 Mar 1;81(5):1230-1239
pubmed: 33419773
Nat Genet. 2016 Jan;48(1):30-5
pubmed: 26569126
Eur J Cancer. 2019 Jul;116:116-136
pubmed: 31195356
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
JAMA Oncol. 2018 Jul 1;4(7):953-961
pubmed: 29800115
Eur Urol. 2014 Jan;65(1):169-76
pubmed: 22841674
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Eur Urol. 2013 May;63(5):800-9
pubmed: 23219374
Nat Commun. 2017 Jan 09;8:13671
pubmed: 28067867
J Natl Cancer Inst. 2021 Apr 01;:
pubmed: 33792693
Stroke. 2021 Aug;52(9):2882-2891
pubmed: 34039031
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Nat Rev Urol. 2020 Jan;17(1):41-61
pubmed: 31316185
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
Am J Hum Genet. 2015 Oct 1;97(4):576-92
pubmed: 26430803
Elife. 2018 Sep 04;7:
pubmed: 30178746
J Natl Cancer Inst. 2021 Oct 1;113(10):1379-1385
pubmed: 33837773
Br J Cancer. 2012 May 8;106(10):1697-701
pubmed: 22516946
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44
pubmed: 25024180
J Natl Cancer Inst. 2021 Mar 1;113(3):258-265
pubmed: 32778876
J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1586-1593
pubmed: 28329340
Nature. 2021 Feb;590(7845):290-299
pubmed: 33568819
Med J Aust. 2008 Jul 21;189(2):105-9
pubmed: 18637782